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INTRODUCTION
Diabetes  mellitus  (DM)  is  one  of  the  most  common  non-communicable
disease  (NCDs)  globally.  It  is  the  4th  or  5th  leading  cause  of  death  in  most
developed countries and there is substantial evidence that it  is epidemic in many
economically  developing  and  newly  industrialized  countries.  According  to
international diabetes federation (IDF) 5th  edition of Diabetes Atlas, it is indicated
that the number of people living with diabetes is expected to rise from 366 million in
2011 to 552 million by 2030.IDF has also estimated that about 61.3 million people
in India are living with diabetes. There are 3 main types of diabetes: Type I, TypeII,
and Gestational diabetes mellitus. Type II is the most common form of diabetes and
accounts for 90 to 955 of Diabetes cases. Chronic hyperglycemia without proper
management  can  also  lead  to  various  short  term  and  long  term  secondary
complications, both of small and big, vascular nature which may be determined as
the  main cause of mortality and  morbidity in type 2 diabetic patients all over the
world.
DEFINITION OF TYPE II DIABETES
Type II diabetes is a chronic metabolic disorder which is characterized by the
insulin resistance, impaired islets of beta cell function, and multiple other metabolic
or  endocrine abnormalities.  Because of multifactorial  pathogeneses restoration of
normoglycemia is difficult to be achieved. This requires many multiple anti diabetic
medications that have different mechanism of action and this agent can be used in
combination  to  produce  additive  effect.  A wide  range  of  antibiotic  agent  with
different mechanism of action can also be used to treat diabetes.
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ETIOLOGY OF DIABETES
• Diabetes mellitus which affect people in childhood is known as type II diabetes,
they can also be called as non-insulin dependent diabetes, they are commonly
affected on the onset of the adolescence. This has  become a common disorder
that can be characterized by high level of glucose in the blood and other body
fluids like urine ,  it has been found out that the disease occurs mainly due to  an
increase in the resistance of the body to insulin.
•  Many factors has been determined that may lead to diabetes mellitus, or at least
that can make this type of diabetes mellitus to a worse condition.
• These factor include, uncontrolled fat deposit in the body (in which around fifty
five percent of type 2 diabetes patients are obese at diagnosis) ,high BP, high
cholesterol  level  along with elevated   hyperlipidemia and with the  condition
often determined as  metabolic syndrome. There are many other causes also,
which  may  include  problems  like  thyrotoxicosis,  Cushing’s  syndrome,
pheochromocytoma, acromegaly chronic pancreatitis and the use of certain other
drugs.
• Increased obesity can  leads to increased insulin resistance in the body  which
can easily develop the chance of sudden Type 2 diabetes, most likely cause is
that because adipose tissue present mainly in the abdominal region and around
the internal organs could be the main source of several chemical signals to other
tissues present in the body likes hormones and cytokines.
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•  the type 2 dm has more possibilities of inheritable genetic connections, which
can be received from their parents or other close relatives .
• Mutation to the Islet amyloride Polypeptide gene which can results in an earlier
onset,  which  is  a  more  severe  and  chronic  form  of  diabetes  .  Many
environmental  factors  like  weight,  diet  and  lifestyle  play  a  big  role  in  the
development  of  the   type  2 diabetes,  in  addition  to  any genetic  or  inherited
component.
• These may  include thiazide diuretics ,atypical  anti-psychotic  drugs,  Calcium
channel  blockers,  corticosteroids,  beta  blockers,  proteaseinhibitors
fluroquinones, phenothiazines, somatropin, , etc.
• The mechanisms by which these drugs can lead to an increase in the insulin
resistance of the body is different and varies in different drugs.
• High blood sugar level in the body can be a serious condition that can affects
practically each and every organ and the organ systems  of the body.
• So ,  a person who is  affected  to  DM  should make all  possible efforts  and
changes to  their  lifestyle so as  to  keep their  blood sugar  level  in  check and
control.
LABORATORICAL INVESTIGATION OF TYPE 2 DIABETES
• FASTING  PLASMA GLUCOSE : BASIC BUT IMPORTANT
FPG is  the  very basic test  for  DM.FPG is  useful  for  both diagnosis  and
following up. This is a basic test but it is very important. The pre-analytical factor
seems to  be strongly affecting the FPG results.  The  patient  preparation must  be
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gently controlled. It is a requirement toverify the fasting stage of the patients normal
value; 70-110mg/dl.
• POSTPRANDIAL GLUCOSE  :  AN  ALTERNATIVE  MEASUREMENT
FOR BLOOD GLUCOSE  
Sometimes, the FPG test is not feasible hence the postprandial glucose is
examined. This might be another alternative clue for diagnosis of DM. One with
abnormal high postprandial glucose level needs further verification by FPG test. The
postprandial glucose is an actual application of measurement of chemical in blood
with interference (from diet).Normal values: 70-140
• GLYCATED  END  PRODUCT:  TOOLS  FOR  MONITORING  FOR
DIABETIC COMPLICATION
Glycated end product is a specific in vivo substance that can be generated in
caste of poorly controlled DM patients .This is the result from the reaction between
proteins  in  blood  (normally  hemoglobin  or  albumin)  with  excessive  glucose  in
blood.  The  nature  of  energy  aberration  induction  of  the  reaction  results  in
complications of DM
• INSULIN TEST: A DIRECT MEASUREMENT OF HORMONE
Insulin is the major hormone in regulation of blood glucose homeostasis. The
abnormality of insulin physiology is mentioned as an important underlying for DM,
normal value 0.0-24.91U/ml.
When diabetes is not well-controlled, the sugar level in the blood goes up.
This is called hyperglycemia. High blood sugar can cause damage to many parts of
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the diabetes patient body, especially Kidneys, heart, blood vessels, eyes, feet, nerves.
Diabetes can also cause high blood pressure and hardening of the arteries (called
arteriosclerosis). These can lead to heart and blood vessel disease.
 HEMOGLOBIN A1C TEST
The HbA1c test is a laboratory test, which indicates blood glucose control
over  last  three  months.  HbA1c  is  formed  when  glucose  in  the  blood  binds
irreversibly to hemoglobin to form a stable glycated hemoglobin complex. Since it is
irreversible, it stays through out the life span of red blood cells i.e. 90-120 days.
Therefore HbA1c testing serves as a reliable indicator of overall glucose control of
previous 90 days. Monitoring HbA1c allows doctor to assess long-term compliance
with management protocols, such as diet, exercise and medication. The test shows
whether  the blood glucose is  close to normal or  too high. An HbA1c test  result
between 4 to 5.5 % is considered normal. HbA1C value less than 7% in a diabetic
means blood glucose is under control. A change in a treatment plan is almost always
needed if the test result is over 8%. Studies conducted in people with diabetes have
shown that lower the HbA1c number, greater the chance of staying healthy & will
slow or prevent the development of serious eye, kidney and nerve disease. People
with diabetes should get  the HbA1c test  at  least  two times a year  if their blood
glucose is in the target range and stable. If they are taking insulin, if their treatment
changes or if their blood glucose stays too high, they should get the HbA1c test at
least every 3 months until their blood glucose level improves. It is important to note
that HbA1c testing is not considered as replacement of blood glucose testing. The
blood glucose test is very effective and common test for the measurement of glucose
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level in the body, HbA1c test value gives an idea of average blood glucose levels
over preceding 3 months.
HbA1C mg/dl
NORMAL <5.5
ABNORMA
L >5.5
TREATME
NT >6
ORAL GLUCOSE TOLERANCE TEST
• Diabetes is diagnosed if glucose level is higher than 200 mg/dl after 2 hours
Diabetes screening is recommended.
• Overweight adults (BMI greater than 25) who have other risk factors.
• Adults over age 45 every 3 years.
MANAGING BLOOD SUGAR BY SELF TESTING
Self-testing means checking the blood sugar at home themselves. Checking
blood sugar levels at home and writing down the results will tell how well is being
manage.
A device called a glucometer can give an exact blood sugar reading. There
are different types of devices. Usually, pricking the finger with a small needle called
a lancet. This gives a tiny drop of blood. Place the blood drop on a test strip and put
the strip into the device. Results are given within 30 - 45 seconds.
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A health  care  provider  or  diabetes  educator  will  help set  up  an at  home
testing schedule for the Diabetes patients. The doctor will help to set the blood sugar
goals.
• Most people with type 2 diabetes only need to check the blood sugar
once or twice a day.
• Check the blood sugar levels few times a week, if the blood sugar
levels are under control.
• Self-testing can be done after wake up, before meals, and at bedtime.
• Testing should be done when the patient are sick or under stress.
The results  of the test  can be used to change patient’s  meals,  activity,  or
medications to keep blood sugar levels in the right range. Testing can identify high
and low blood sugar levels before to attaining serious problems.
Advice the patient to keep a record of blood sugar by themselves and with
health careprovider. This will help them to identify whether they are having trouble
managing diabetes.
CO-MORBIDITY
Co-morbidity is defined as the occurrence of one or more chronic conditions
in the same person with an index-disease, occurs frequently among patients with
diabetes.  Currently, integrated diabetes care programs focus on diabetes-related co
morbidities like cardiovascular diseases, retinopathy, nephropathy and diabetic foot. 
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However,  patients  with  diabetes  do  not  only  have  diabetes-related  co
morbidity but also have non diabetes-related co morbidity, such as depression and
musculoskeletal diseases.  With the ongoing population aging of Western societies,
not only the number of patients with diabetes is expected to increase, but also the
number of patients with diabetes with co morbidity. This implies that the current
single disease management approach is not applicable to a large part of the patients
with diabetes in the future.
Co-morbidity among patients with diabetes is associated with considerable
consequences for  health  care and related costs.  Co-morbidity has  been shown to
intensify health care utilization and to increase medical care costs for patients with
diabetes.  However,  most  studies  have  been  focused  on  one  health  care  service,
mainly hospital care, or limited their analyses to one additional co morbid disease.In
addition previous studies on multidisciplinary health care utilization were based on
self-reported questionnaires instead of health care registration data. We elaborated
on these  studies  by taking into account  a  broad spectrum of  co morbidities  and
focusing on multiple health care services by linking data of different  health care
registrations.
A better understanding of the effects of co morbidity on the type and volume
of medical health care utilization is essential to gain insight into future health care
demands of patients with diabetes.
DIABETIC RETINOPATHY
Diabetic  Retinopathy  (DR)  is  a  vascular  disorder  affecting  the
microvasculature of the retina. Diabetic Retinopathy is a complication of diabetes
Dept. Of Pharmacy Practice 8 JKKMMRF College of Pharmacy
Chapter 1 Introduction
and a leading cause of blindness. It occurs when diabetes damages the tiny blood
vessels inside the retina, the light-sensitive tissue at the back of the eye. The patient
having diabetic retinopathy might not notice any changes to the vision at first. But
over  time,  diabetic  retinopathy  can  get  worse  and  cause  vision  loss.  Diabetic
retinopathy usually affects both eyes. It is estimated that diabetes mellitus affects 4
per cent of the world’s population, almost half of whom have some degree of DR at
any given time. DR occurs both in type 1 and type 2 diabetes mellitus and has been
shown that nearly all type 1 and 75 per cent of type 2diabetes will develop DR after
15 yrs duration of diabetes as shown in earlier epidemiologicalstudies2, 3. In the
western  population,  DR has  shown to  be  the  cause  of  visual  impairment  in  86
percent of type 1 diabetic patients and in 33 per cent of type 2 diabetic patients In
India with the epidemic increase in type 2 diabetes mellitus as reported by the World
Health  Organization  (WHO),  diabetic  retinopathy  has  been  becoming  a  very
important   cause of  visual  disability and other  visual  problems. Visual  disability
from diabetes is a big public health problem.  this morbidity is largely preventable
and  curable.  The  quality  of  life  can  be  preserved  if  managed  with  timely
intervention. This review aims at providing an overview of diabetic retinopathy in
the Indian scenario.
DIABETIC NEUROPATHY
Diabetic neuropathies are a group  of nerve disorders that may be caused by
DM. nerve damage throughout the body may be observed in dm patients over time
and this is a critical condition. In some cases for some people nerve damage may
occur without any symptoms  while for some others the damage may be followed
with symptoms such as tingling, pain, or numbness loss of feeling in the hands,
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arms, feet, and legs. These nerve damage or disorders may affect every organs in the
body,  including important  organs  like  the  heart,  digestive  tract,  and  sex  organs.
Neuropathy is observed in about 60 to 70 % of DM patients, People with diabetes
can develop nerve problems at any time without any prediction, but risk rises with
neuropathy are seen in people who have had diabetes for at least 25 years. In people
who have problems in controlling their blood glucose, also called blood sugar, those
with high levels of blood fat and high BP and those who are overweight, diabetic
neuropathies appear to be more common and chronic. The no of nerves affected or
the type of nerve affected may make changes in the symptoms also. Some people
with nerve damage may have no symptoms at all while for others, symptom like the
numbness, tingling, or pain in the feet can be observed. Symptoms can usually be
minor at first, and because most nerve damage occurs over several years, mild cases
may go unnoticed for a long time. Symptoms can involve the sensory, motor, and
autonomic or involuntary nervous systems. In some people, mainly those with focal
neuropathy, the onset of pain may be sudden and severe. 
SYMPTOMS OF NERVE DISEASES
• The muscles of the feet or hands get wasted.
• Tendency for nausea, or vomiting and Indigestion.
• Diarrhea and constipation.
• faintness due to a drop in BP if sitting or standing up.
• Numbness, tingling, or pain in the toes, feet, legs, hands.
• Problems while urination.
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• Erectile dysfunction may be seen in  men or vaginal dryness can be observed
in  women.
DIABETIC NEPHROPATHY
Diabetic  Nephropathy  is  the  leading  cause  of  kidney  disease  in  patients
starting renal replacement therapy and affects 40% of type 1 and type 2 diabetic
patients. It  increases the risk of death, mainly from cardiovascular causes, and is
defined by increased urinary albumin excretion (UAE) in the absence of other renal
diseases. Diabetic nephropathy is categorized into stages: micro albuminuria (UAE
20 g/min and 199 g/min) and macro albuminuria (UAE 200g/min).Hyperglycemia,
increased blood pressure levels, and genetic predisposition are the main risk factors
for the development of diabetic nephropathy. Elevated serum lipids, smoking habits,
and the amount and origin of dietary protein also seem to play a role as risk factors.
Screening for micro albuminuria should be performed yearly, starting 5 years after
diagnosis in type 1 diabetes or earlier in the presence of puberty or poor metabolic
control in patients with type 2 diabetes; screening should be performed at diagnosis
and yearly thereafter. Patients with micro- and macro albuminuria should undergo an
evaluation regarding the presence of co morbid associations, especially retinopathy
and macro vascular disease. (100 mg/dl) are effective strategies for preventing the
development of micro albuminuria, in delaying the progression to more advanced
stages of nephropathy and in reducing cardiovascular mortality in patients with type
1 and type 2 diabetes.
HYPERTENSION
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The prevalence of hypertension in the general population is about 20 to 30%
andmorewithincreasingage and incertain ethnic groups. Isolated diastolic or systolic
-diastolic  hypertension is  more common in younger  people (<40 years)  whereas
systolic hypertension is more frequent in the elderly in olderpeople. The major cause
of rising systolic and pulse pressurewith age is an increase in large artery stiffness.
Associated factorsinclude obesity and reduced physical activity.
Hypertension is  more prevalent  in patients with diabetes than in the non-
diabetic  population,  and  early  identification  and  effective  management  of
hypertension is  paramount in  the care of people with diabetes.  Adults  with both
diabetes and hypertension have more renal disease and atherogenic risk factors than
the  general  population,  including  dyslipidemia,  elevated  fibrinogen  and  left
ventricular hypertrophy. Having both diabetes and hypertension has been shown to
double the risk of cardiovascular events, cardiovascular mortality and total mortality.
HYPERLIPIDEMIA
Hypercholesterolemia  is  a  disorder  characterized  by high  levels  of  blood
cholesterol. Cholesterol is manufactured primarily in the liver and then carried to the
cells throughout the body by low-density lipoprotein (LDL).  Because cholesterol
and other fats do not dissolve in water, they cannot travel through the body unaided.
Lipoproteins are particles formed in the liver to transport cholesterol and other fats
through the bloodstream. Cholesterol is returned to the liver from other body cells
by another lipoprotein, high-density lipoprotein (HDL). From there, cholesterol is
secreted into the bile, either unchanged or after conversion to bile acids.
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Cardio vascular diseases are the leading cause death in many countries in the
world. Coronary heart disease is the most common single case of death in the United
States.  Hypercholesterolemia (HC)  is  a  well-established  major  risk  factor  for
coronary heart disease. The increased risk of coronary artery disease subject with
diabetes mellitus can be partially explained by the lipoprotein abnormalities with
diabetes mellitus.
PRECAUTIONS TO BE TAKEN BY DIABETIC PATIENTTS
• With an interval of three months the dm patients should see their health care
provider and should take proper diagnostic care.
• Always check the bones and skin of the  feet and leg. 
• Observe whether the patients feet are becoming numb and insensitive.
• Ophthalmoscope can be used to observe the back part of the eyes; it is a special
lighted device.
• Blood pressure should be checked at  least  one in  a  year  (blood pressure
should be always at a normal rate 120/80 mm/hg.
•  Hemoglobin A1C test (HbA1c) should be conducted  every 6 months even if
the diabetes is well controlled and cured; or every 3 months.
•  cholesterol level and triglyceride levels should be checked yearly 
• Kidney function test should be conducted yearly to check whether they are
working properly. (microalbuminuria , serum creatinine level, etc.).
• Consult your eye doctor yearly or often , if the patient is diabetic.
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• Consult the dentist every 6 months for a thorough dental cleaning and check
up.  The  dentist  and  hygienist  should  know  about  the  patient  diabetes  and
diabetes history.
• The goal of treatment at first is to lower high blood glucose levels. The long-
term goals of treatment are to prevent problems from diabetes.
The main treatment for type 2 diabetes is exercise and diet.
MEDICATION TO REDUCE THE BLOOD GLUCOSE LEVEL
METFORMIN
Metformin  is a biguanide medicine. Its main function is to  lower the blood
glucose level in the body mainly by lowering  the amount of sugar  that the liver
releases into the bloodstream. The sensitivity of the body to produce more insulin is
also increased along with the increase of  the action of the produced insulin on the
glucose molecules. It has also been shown in studies that Metformin lower the risk
of other complications of diabetes mellitus such as heart attack ,high BP , weakness,
stroke, etc.
The first drug advised if blood glucose level  is not controlled by lifestyle measures
by the physician is metformin alone. If the patient is overweight, as it is less likely
than some other glucose-lowering tablets to cause weight gain metaformin would be
the  advised  drug.  Metformin  generally  does  not  produce  the  problem  of
hypoglycemia like some of the other glucose level reducing drugs, this is a good
advantage  that  the  medicine  has  over  the  other  drugs.  Metformin  can  also  be
consumed  along  with  other  glucose  lowering  drugs,  it  does  not  produce  much
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adverse reactions and problems which can be considered as an advantage of the
drug.
ADVERSE REACTIONS OF METFORMIN
Some people feel sick or have mild diarrhea When metformin is first started
to be administered,. if they start with a low or mild dose and then gradually build up
the dosage to the usual level over a few weeks then those problems which may be
caused can be avoided . If  side-effects occur, they tend to ease off with time. Other
side-effects are not so common and usually does not produce much problems.
SULFONYLUREA MEDICINES USED FOR DM
There are many types of sulfonylurea medicines also which can be used for
DM. some of these can be categorized as glimepiride, gliclazide, and glipizide. The
main action these drugs produce on the body to lower dm is by increasing the insulin
produced by the pancreas, they act on the pancreas to secrete more insulin as the
body demand increases  during DM  .If the patient have type 2 diabetes mellitus ,
and still  make insulin in the  pancreas.  It  does not make enough to keep blood
glucose level normal and keep it constant.
A sulfonylurea  is  most  often  used  if  the  patient  cannot  take  metformin
because  of  side-effects  or  other  reasons like  allergy or  such  problems,  or  if  the
patient are not overweight. Usually the starting dose is very low, and the dose can be
increased necessarily  every few weeks until there  the blood glucose level are under
control . sulfonylurea can be consumed along with other glucose lowering drugs if
they are not properly affecting in the body to keep blood glucose under normal level.
ADVERSE REACTIONS OF SULPHONYLUREA 
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As sulfonylurea’s boost the level of insulin in the body, hypoglycemia is a
possible problem that can be produced. This is an uncommon problem and unlikely
to happen if they:, don't miss meals, and don't drink too much alcohol , have regular
meals. Trembling , sweating, anxiety, blurred vision, tingling lips, paleness, mood
change,  vagueness  or  confusion,  etc  includes  the  symptoms  of  hypoglycemia.
Sugary  drink or some sweets can be taken to treat hypoglycemia. 
Some weight gain is a very common side-effect that may be caused. Other
side-effects  are  uncommon  and  rare.  Feeling  sick  (nausea),  mild  diarrhea  and
constipation, etc can be the other side-effects caused.
THIAZOLIDINEDIONES
  They are commonly called glitazones, thiazolidinedione’s, they works by
increasing the sensitivity of body's cells to insulin so that  more glucose is taken into
cells for the same amount of insulin in the bloodstream and thus reduce the blood
glucose  level  of  the body.  They are  not usually used alone,  they are commonly
administered along with metformin or sulfonylurea’s
ADVERSE REACTION OF THIAZOLIDINEDIONES
Patients with heart failure, should not be administered with this drug  as this
may worse the condition. There is also a slight risk of liver damage also prevails
over the use of this drug. Therefore, they should be a blood test to check on the liver
function before starting these type of drugs. The tests should be repeated or done
regularly to determine the normal rate of heart and kidney functions as long as these
drugs are consumed. Weight gain is a side-effect  common seen, probably due to
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fluid  retention  in  the cells.  Hypoglycemia is  an  uncommon and  rare  side-effect.
Other possible side-effects are uncommon and very rare.
ACARBOSE
Acarbose   works  by  delaying  the  absorption  of  carbohydrates  (which  are
broken down into glucose) from the gut. Therefore, it can reduce the peaks of blood
glucose which may occur after meals. It is an option if they are unable to use other
tablets to keep the blood glucose level down. It can also be used in addition to other
glucose-lowering  tablets.  However,  many people  develop  gut-related  side-effects
when taking acarbose, such as bloating, wind, and diarrhea. Therefore, it is not used
very often.
INSULIN
Insulin injections decrease the blood glucose level. some people with type 2
diabetes  need  insulin.  It  may be  advised  if  the  blood  glucose  level  is  not  well
controlled  by  tablets.  The  dose  and  type  of  insulin  used  varies  from person  to
person. Sometimes insulin is used alone. However, sometimes it is used in addition
to along with the tablets. The doctor or practice nurse should give detailed advice on
how and when to use it. Some weight gain is a common side-effect. Weight gain
may be  less  of  a  problem if  the  use  of  insulin  in  combination  with  a  glucose-
lowering tablet such as metformin. Hypoglycemia is a possible complication.
EXENATIDE  AND  LIRAGLUTIDE-GLUCAGON-LIKE  PEPTIDE-1
MIMETICS
Exenatide and liraglutide are treatments given as an injection. They work in a
similar way to the action of the naturally occurring hormone glucagon-like peptide-1
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(GLP-1). These actions include stimulating insulin secretion in response to glucose
and preventing glucagon (a hormone which raises blood sugar) release after meals.
Exenatide and liraglutide are usually used as an add-on treatment to improve
glucose control when insulin treatment is not acceptable. There is a once weekly
treatment  available.  Side-effects  may  include  hypoglycaemia,  feeling  sick  and
headaches. People receiving this treatment usually lose weight.
PHARMACIST’S ROLE IN MANAGEMENT OF DIABETES
Two large  prospective  intervention studies  include the Diabetes  Care  and
Complications Trial in type one diabetes and the UK Prospective Diabetes Study in
type two diabetes. These studies demonstrated that intensive diabetes management
resulted  in  lower  rates  of  micro  vascular  complications.  The  Epidemiology  of
Diabetes Interventions and Complications trial, a follow up of the DCCT, has shown
that  initial  intensive  management  has  resulted  in  lower  rates  of  retinopathy,
nephropathy, neuropathy, and macro vascular disease. Pharmacists are an integral
part of the health care delivery system in the America and are the most accessible
health  care  peoples  in  most  communities.  The  Pharmacists  may help  bridge  the
education gap, since it is has been reported that only 30% of patients receive formal
diabetes  education.  The Pharmacists  are  uniquely positioned  to  provide  diabetes
education since patients with diabetes see their pharmacists seven times more often
than  they  see  their  primary  care  physician.  There  are  currently  over  230,000
pharmacists in the America. 
Almost all medically managed patients with Diabetes interact on an ongoing
basis with a pharmacist. As such, pharmacists may have a profound influence on
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improving  the  lives  of  the  patients  with  diabetes  whom they  see  in  their  daily
practice. The role of the pharmacist in DSMT is well established. Common practice
sites  where  DSMT is  provided  include  community pharmacies,  ambulatory care
settings,  hospitals, long-term care facilities,  rehabilitation facilities, and physician
offices. Other sites may include, but are not limited to, the Public Health Service
(e.g.,  Indian  Health  Service)  clinics,  Community  Health  Centers,  and  private
consulting practices.  Numerous studies  have shown that  pharmacist  interventions
improve medication adherence, treatment outcomes, and quality of life for patients
with diabetes.  Studies  have also shown that  pharmacists have demonstrated cost
savings by providing diabetes  care in community settings  as  well  as in Veterans
Health Administration Clinics Pharmacists have even build up d a business model to
provide pharmacy services. 
The  pharmacists  are  able  to  build  strong  relationships  with  patients  and
become  a  reliable  source  of  information.  Pharmacists  may  also  have  ongoing
communication with physicians and may serve as the ‘bridge’ between other health
care  providers  and  the  patient,  thus  ensuring  continuity  of  care.  In  addition,
pharmacists  may  provide  on-going  recommendations  to  the  patients  and  their
providers to optimize diabetes care. 
These factors position Pharmacists to profoundly impact the health outcomes
and  quality  of  life  for  their  patients  with  diabetes.  A  variety  of  pharmacist
interventions to improve diabetes outcomes have been reported by pharmacists in
community  pharmacies.  These  interventions  included  diabetes  education  and
pharmacologic management to improve glycemic control as well as lowering blood
pressure  and  cholesterol.  These  programs  were  done  in  collaboration  with
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physicians,  local  formal  diabetes  education  programs,  and  the  patient’s  insurer.
Pharmacist intervention was provided in concert with regular physician follow-up
visits and formal diabetes education programs offered by local diabetes education
Centers.  Over  50%  of  patients  had  an  improvement  in  A1C  values  relative  to
baseline. Average LDL- and HDL cholesterol levels improved at every visit. Patients
were  either  referred  by  their  primary  care  providers  or  could  self-refer  for  a
pharmacist  consultation  to  evaluate  A1C  and  lipid  results,  blood  pressure,  and
receive diabetes education. 
The Pharmacists provided three one-hour sessions and quarterly follow-up
visits to assess patient progress toward goals. After each visit, the pharmacist sent a
report  of  the  patient’s  lab  and  blood  pressure  with  Recommendations  for  drug
therapy changes to the patient’s  physician.  The Scope of Practice for pharmacist
diabetes  educators  defines  a  range  of  practice  for  the  specialty,  and  provides  a
framework for appropriate and effective pharmacist practice in diabetes care. All
pharmacists must be knowledgeable of the disease state and coexisting diseases, to
provide safe, competent care to persons with, or at risk, for diabetes. As the intensity
of  care  increases,  so  must  a  pharmacist’s  knowledge  base  increase  through
experience,  continuing  education,  individual  study,  mentorship,  and  potentially,
certification.Pharmacists  providing  diabetes  care  utilize  established  principles  of
education  strategies,  learning  theory,  and  provide  lifestyle  counseling  to  help
patients effectively manage their disease. Instruction is individualized for persons of
all  ages,  incorporating cultural  preferences,  health beliefs,  and preferred learning
styles of the patient.
Dept. Of Pharmacy Practice 20 JKKMMRF College of Pharmacy
Chapter 2 Literature Review
LITERATURE REVIEW
Jaansidorov,Roberts  hull  et  al  (2002)observed  whether  Diabetes  Disease
Management Save Money and Improve Outcomes Little are known about the impact
of disease management programs on medical costs for patients with diabetes. This
study compared health care costs for patients who fulfilled health employer data and
information  set  (HEDIS)  criteria  for  diabetes  and  were  in  a  health  maintenance
organization (HMO)-sponsored disease management program with costs for those
not in disease management. We retrospectively examined paid healthcare claims and
other measures of health care use over 2 years among 6,799 continuously enrolled
Geisinger  Health  Plan  patients  who  fulfilled  HEDIS  criteria  for  diabetes.  Two
groups were compared: those who were enrolled in an opt-in disease management
program and those who were not enrolled. We also compared HEDIS data on HbA1c
testing,  percent  not  in  control,  lipid  testing,  diabetic  eye  screening,  and  kidney
disease screening. All HEDIS measures were based on a hybrid method of claims
and chart audits, except for percent not in control, which was based on chart audits
only.
Michele,  eisler, M. Smith et al (2003conducted a Patients’ Assessments of Their
Diabetes Self-Management Correlate With Actual Glycemic Control and Receipt of
RecommendedDiabetes  Services  Although  patient  diabetes  self-management  is  a
key determinant of health outcomes, there is little evidence on whether patients own
assessments  of  their  self-management  correlates  with  glycemic  control  and  key
aspects  of  high-quality  diabetes  care.  1We  explored  these  associations  in  a
nationwide  sample  of  Veterans’  Affairs  patients  with  diabetes  We  abstracted
information on achieved levelof glycemic control (HbA1c) and diabetes processes of
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care (receipt of HbA1ctest, eye examination, and nephropathy screen) from medical
records  of  1,032  diabetic  patients  who  received  carefrom  21  Veterans’ Affairs
facilities  and  had  answered  the  Diabetes  Quality  Improvement  Program  survey
in2000.  The  survey  included  sociodemographic  measures  and  a  five-item  scale
assessing  thepatients’ diabetes  self-management  (medication  use,  blood  glucose
monitoring, diet, exercise, and foot care [0.68]). Using multivariable regression, we
examined the associations ofpatients’ reported self-management with HbA1clevel
and receipt of each diabetes process of care.We adjusted for diabetes severity and
co-morbidities,  insulin use,  age, ethnicity, income, education, use of VA services,
and clustering at the facility level.
McGowan et al (2011)studied theefficacy of diabetes Patient Education and
Self - Management Education in Type 2 DM the goal of this randomized, controlled
trial was to compare the 6-month efficacy of didactic diabetes patient education to a
model that augmented this education with a self-management program. Adults   with
type II diabetes wererandomly assigned to a group that  received diabetes patient
education or to a group that received this education augmented by a community self-
management program. Outcome measures were taken at baseline and six months.
Analysis included pre-and 6 month-post–program paired comparison for each group;
a  comparison  of  change  between  groups;  and  an  intent-to-treat  comparison  of
change  between  the  groups.  At  baseline,  there  were  no  between-condition
differences  with  respect  to  behavioral  or  biological  outcomes  or  healthcare
utilization.  The  pre-  and  6-month-post–program  comparison  found  statistically
significant improvements in both   groups in terms of glycated   hemoglobin (A1C)
and weight, and the experimental group had statistically significant improvements in
Dept. Of Pharmacy Practice 22 JKKMMRF College of Pharmacy
Chapter 2 Literature Review
4 additional outcomes. A 12-month analysis   found   that   baseline   scores   were
statistically  forbothA1Candweightintheexperimentalgroup  statistically  higher  than
baseline A1C in the control group.
Rhonda M, Wendy et al (2005) studied about the Effect of a pharmaceutical
patient education program on Vascular Risk Factors in Type 2Diabetes examine the
effect of a 12-month PCprogram on vascular risk in type 2 diabetes. We recruited
198 community-based patients  randomized to pharmaceutical  care or  usual  care.
Pharmaceutical care patients had face-to-face goal-directed medication and lifestyle
counseling at baseline and at 6 and 12 months plus 6-weekly telephone assessments
and provision of other educational material. The main outcome measure was change
in HbA1cA diabetes-specific risk engine was used to estimate changes in 10-year
CHD and stroke risk in patients without a history of cardiovascular disease. At total
of 180 patients (91%) completed the study. Mean (95% CI) reductions were greater
in PC case subjects (n 92) than control subjects (n 88) for hemoglobinbA1c and
systolic 14 mmHg [19 to9] vs.7 [11 to2] and diastolic 5 mmHg blood pressure (P
0.043). The improvement in hemoglobinA1c persisted after adjustment for baseline
value  and  demographic  and  treatment  specific  variables.  The  median  10-year
estimated risk of a first chronic heart disease event decreased in the PC case subjects
but not in the control subject. A 12-month PC program in type 2 diabetes reduced
glycemia and blood pressure. Pharmacist involvement contributed to improvement
in HbA1cindependently of pharmacotherapeutic changes. 
Martham,  F  Unnel,  Tammy  L et  al  (2009) conducted  a  Diabetes  self-
management  education (DSME) is  a  critical  element  of  care for  all  people with
diabetes  and  is  necessary  in  order  to  improve  patient  out-comes.  The  National
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Standards  for  DSME  are  designed  to  define  quality  diabetes  self-management
education  and  to  assist  diabetes  educators  in  a  variety  of  settings  to  provide
evidence-based  education.  Be-cause  of  the  dynamic  nature  of  health  care  and
diabetes-related research, these Standards are reviewed and revised approximately
every  5  years  by  key  organizations  and  federal  agencies  within  the  diabetes
education  community.  A  Task  Force  was  jointly  convened  by  the  American
Association of Diabetes Educators and the American Diabetes Association in the
summer  of  2006.  Additional  organizations  that  were  represented  included  the
American Dietetic Association, the Veteran’s Health Administration, the Centers for
Disease  Control  and  Prevention,  the  Indian  Health  Service,  and  the  American
Pharmaceutical  Association.  Members  of  the  Task  Force  included  a  person  with
diabetes;  several  health  services  researchers/behaviorists,  registered  nurses,  and
registered dietitians; and a pharmacist.  The Task Force was charged with re-viewing
the  current  DSME  standards  for  their  appropriateness,  relevance,  and  scientific
basis.  The  Standards  were  then  re-viewed  and  revised  based  on  the  available
evidence and expert consensus. The committee convened on 31 March 2006 and
September 2006, and the Standards were approved 25 March 2007.Diabetes self-
management  education  (DSME)  is  the  ongoing  process  of  facilitating  the
knowledge,  skill,  and  ability  necessary  for  diabetes  self-care.  This  process
incorporates the needs, goals, and life experiences of the person with diabetes and is
guided by evidence-based standards. The overall objectives of DSME are to support
informed  decision-making,  self-care  behaviors,  problem  solving  and  active
collaboration with the health care team and to improve clinical  outcomes, health
status, and quality of life.
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Kelly  R.  Ragucci.  Fermo et  al  (2005) evaluated  the  effectiveness  of
pharmacist-administered diabetes mellitus education and management services on
selected  diabetes  performance  measures.  Additional  goals  were  to  compare
outcomes with goals specified for patients with diabetes by the National Committee
for Quality Assurance (NCQA) and identify areas for improvement each patient was
assessed for hemoglobin A 1c (A1C) values, blood pressure, low-density lipoprotein
cholesterol (LDL) levels, and aspirin use at baseline and at 1 year after enrollment.
Cost avoidance comparators were calculated for those patients with reductions in
A1C of at least 1%. Average A1C at 1 year was 7.8% (range 4.5-13.9%) versus 9.5%
(range 5.4-19%) at baseline (change -1.7%, p<0.05).  Seventy-two patients (38%)
experienced a 1% or greater reduction in A1C. Average blood pressure decreased
over the study period from 141/79 to 135/75 mm Hg (p=0.007), but average LDL
levels did not change to a statistically significant extent (114 to 112 mg/dl, p>0.05).
Aspirin  use  increased  from 34% at  baseline  to  73% at  1  year  (p<0.0001).  The
program achieved the A1C and LDL values required to qualify for NCQA diabetes
recognition. Based on an estimated savings for each 1% decrease in A1C.Diabetes
management services from clinical pharmacists achieved significant improvements
in  A1C  values,  blood  pressure,  and  aspirin  use.  Continued  efforts  in  diabetes
education and management are needed to further improve clinical, economic, and
humanistic  outcomes. Approximately  6.3%  of  the  United  States  population  has
diabetes mellitus,  which ranks as  the sixth leading cause of  death and generates
annual costs above million. Numerous guidelines specify optimal care for patients
with diabetes, but a gap exists between these recommendations and the actual care
administered. [2]According to the American Diabetes Association (ADA), the target
for long-term glycemic control in patients with diabetes is hemoglobin A 1c (A1C)
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below 7%. [3] Patients with diabetes are at increased risk of cardiovascular events;
thus, additional treatment goals include achieving blood pressure below 130/80 mm
Hg,  low-density  lipoprotein  cholesterol  (LDL)  levels  below 100 mg/dl  (or  <  70
mg/dl for those at particularly high risk), and daily aspirin therapy.
, Ali Mohammad Sabzghabaee ShadiFarsaei et al  (2010 )  The study was
conducted to evaluate the effect of a clinical pharmacists patient education program
for type 2 diabetic patients at  Isfahan Endocrine & Metabolism Research Center
from 04/2008 to 01/2009. This   randomized controlled clinical trial, the total of 172
patients with uncontrolled type 2 diabetes were selected and randomly allocated into
control and study groups. After that written consent, the intervention group received
an  educational  program  about  oral  anti-hyperglycemic  medications,  adherence,
diabetes dairy log and pill box usage. Patient's glycemic control in the intervention
group  was  followed  for  three  months  through  either  telephone  or  face  to  face
interviews with the pharmacist. Fasting blood glucose and HbA1c were measured at
the start and end of the pharmacists drug education program for both intervention
and control groups. After a three months follow-up, mean fasting blood glucose and
HbA1c of the patients in the intervention group decreased significantly compared to
control  group  (p <  0.001).  This  study demonstrates  an  improvement  in  diabetes
management of type 2 diabetics by involving a pharmacist in the multidisciplinary
teams in the outpatient clinics. The results suggest the benefits of adding adherence
education to the diabetic education programs.
Rhonda M.Clifford,Wendy A. Davis et al (2005)examined the effect of a 12-
month pharmaceutical care program on vascular risk in type 2 diabetes. We recruited
198 community-based patients  randomized to PC or  usual  care.  PC patients had
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face-to-face goal-directed medication and lifestyle counseling at baseline and at 6
and  12  months  plus  6-weekly  telephone  assessments  and  provision  of  other
educational material. Clinical, biochemical, and medication-related data were sent
regularly to each patient’s physician(s). The main outcome measure was change in
HbA1c.  A diabetes-specific  risk  engine  was  used  to  estimate  changes  in  10-year
coronary heart disease and stroke risk in patients without a history of cardiovascular
disease. A 12-month PC program in type 2 diabetes reduced glycemia and blood
pressure.PharmacistinvolvementcontributedtoimprovementinHbA1cindependentlyof
pharmacotherapeutic changes. PC could prove a valuable component of community-
based multidisciplinary diabetes care.
Priscilla A Hollander et al (2010) proposed a clinical focused study of type
2  diabetes  co-morbidities  and  treatment  challenges.  The  management  of  type  2
diabetes is designed to reduce disease related complications and enhance long-term
outcomes. Achieving glycemic control is a critical component of this process. The
selection of a drug therapy for minimizing blood glucose is made more challenging
when  patients  already  have  complications  or  co  morbid
conditions.Dispeptidylpeptidase-4(DPP-4)  inhibitors  are  new  classes  of  anti-
hyperglycemic drugs that blocks degradation of incest in hormones. Conclusion of
the study is in such a way that  many patients with diabetes have disease related
complications or co morbid conditions, which can hinder disease management. In
choosing anti hyperglycemic medications, efficacy for improving glycemic control
must be balanced against safety and tolerability issues that can adversely affect these
complications  and  co-morbidities.  DPP-4  inhibitors  provide  a  favorable  balance
between efficacy and safety/tolerability. They offer efficacy similar to other oral anti
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hyperglycemic drugs, but offer tolerability advantages to some agents, including low
risk of hypoglycemia and GI adversities, and weight-neutral effects.
AmitRaval et  al  (2009)reported  study  prevalence  and  determinants  of
depression in type 2 diabetes patients in a territory care center.  Objective of the
study is to investigate the prevalence and determinants of depression in patients with
established type 2 diabetes (T2DM) attending a tertiary care hospital in north India.
Patients with established T2DM were evaluated for depression by administering the
nine-item PHQ-9 (Hindi  version).  Binary logistic  regression  model  was  used  to
examine association between predictor variables and risk of depression. Cronbach
alpha was calculated to assess internal consistency of PHQ-9. The outcome of this
study  is  that  out  of  the  study  patients,  68  (23%)  met  the  criteria  for  major
depression, 54 (18%) for moderate depression and the remaining 178(59%) had no
clinically significant depression. Depression was strongly associated with age >54
yr. (OR) 1.26, 95% CI 1.02-1.67; P,0.05), central obesity (OR 1.34, 95% CI 1.04-
1.64; P,,0.001),  neuropathy (OR 1.94, 95% CI 1.03-3.66; P= 0.002) nephropathy
(OR 1.81, 95% CI 1.02-3.21; P = 0.041), peripheral vascular disease (OR 6.08, 95%
CI 1.07-34.6; P= 0.042), diabetic foot disease (OR 2.32, 95% CI 1.06-5.86; P,0.001)
and pill burden (.4) (OR 1.27, 95% CI 1.01-1.44; P=0.035). However, the likelihood
of  depression  was  not  significant  with  duration  of  diabetes  and  insulin  use.  To
conclude this study showed high prevalence of depression in patients with T2DM.
The risk factors  for  depression  were  age,  central  obesity,  diabetic  complications
particularly neuropathy and diabetic foot disease and increased pill burden.
Hwee-Lin et  al  (2005) reported  a  cross-sectional  study in  the  impact  of
Diabetes mellitus and other chronic medical conditions on the health related quality
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of life. The result of this study is that among 5224 subjects, the prevalence of DM,
HTN, HD and MS where 5.9%, 10.7%, 2.4%, 26.6% respectively. DM lowered SF-
36 scores by more than 2 points on 3 SF -36 scales and lowered SF-6D scores 0.03
points.  Subjects  with  DM and HTN,  DM and HD or  DM and MS experienced
further lowering SF-36 scores exceeding 2 points on at least 6 scales and further
lowering of SF-6D scores by 0.05,0.08 and 0.10 point  respectively.  SF-6D index
scores  generally  reflected  the  pattern  of  influence  of  DM  and  chronic  medical
conditions  on SF-36 scores.  This  study conducted that  DM and chronic  medical
conditions generally reduced HRQoL in this multiethnic general population in an
additive, rather than synergistic or subtractive fashion.
AsliTalazAkca et  al  (2004) reported a cross sectional  sample survey type
study of comparison of psychological adjustment in people with diabetes with and
without  diabetic  foot  ulceration.  Objective  of  the  study is  to  determine  whether
psychological  adjustment to illness differs in people with diabetes between those
who have or do not have diabetic foot ulceration. Two hundred participants with a
diagnosis,  according  to  World  Health  Organization  criteria,  of  type  1  or  type  2
diabetes for at least one year were enrolled in the study. 100 participants receiving
hyperbaric oxygen therapy had diabetic foot ulceration DF and 100 participants had
diabetes without DFU Result of the study is advanced age, low education levels,
long diabetes duration, poor metabolic control and not exercising may be risk factors
for DFU. Participants without DFU had fewer problems in the domainof healthcare
orientation,  vocational  environment,  sexual  relationships,  social  environment  and
Psychological distress than participants with DFU. In participants with DFU; poorer
psychological  adjustment  was  associated  with  poorer  metabolic  control,  lower
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education status, not exercising and retirement. In participants without DFU, women
had  better  psychological  adjustment  than  men.  Also,  participants  exercising  had
better psychological adjustment than participants not exercising.
TatjanaMiclenkovie et al (2004) reported a cross sectional study of influence
of diabetic education on patients wellbeing and metabolic control. The aim of this
study  was  to  evaluate  possible  influence  of  a  structured  teaching  program  for
interactive  group  education  of  diabetic  patients  on  their  overall  wellbeing  and
metabolic  control.  The study included 110 insulin treated diabetic  patients.  They
were  followed  for  one  year  after  a  4-day  structured  teaching  program.  At  re-
education sessions one year after education we noted significant improvement in
metabolic control. HbAlc decreased from 9.2+-1.3 to 7.7+-1.8% Diabetes related
knowledge increased from 49.1+_16.8 to 85.4+-14.3% and patient overall wellbeing
improved from 46.8+-8.3 to 54.8+-5.9 due to reduction of depression and anxiety
and  increase  in  energy  and  wellbeing.  Study  result  confirmed  improvement  of
overall  wellbeing,  metabolic  control  and  diabetes  related  knowledge  in  insulin
treated diabetes patients after a structured education program.
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AIM AND OBJECTIVES
AIM:
To study the prevalence of co-morbidities in type2 diabetes mellitus patients,
the awareness level and the impact of pharmacist’s patient education program.
OBJECTIVES:
• To study the prevalence of co morbidity in type 2 diabetespatients.
• Understand  the  awareness  of  the  patients  about  the  co  morbidities  of
diabetes.
• Implement a patient education program on co morbidities in type 2 diabetes
mellitus patients.
• Understand the impact of patient education program on the awareness levels
of the patients.
• Find out the clinical outcome if any of the Patient education program.
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PLAN OF WORK
The present dissertation work was planned in 4 phases. 
PHASE I:
• Initial study to identify the scope of work
• Literature Survey
• Preparation of study protocol
PHASE II:
• IEC clearance
• Gaining consent from the hospital 
• Design  data  collection  and  educational   formats  with  reference  to
communication, prevalence of co-morbidity, patient education program 
• Get consent from the patients
• Data collection
PHASE III:
• Implement the  pharmacist’s patient education program
• Data collection
PHASE IV:
• Analysis of data
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METHODOLOGY
This chapter comprises of study site, study population, study design, data
collection and data analysis.
STUDY SITE
Study was carried out in the inpatient and outpatient  department of  C.S.I
Mission  Hospital located  at  Malappuram  district  Kerala  having  100  beds  and
specialized in other, general, medicine, pediatric, dermatology and gynecology and a
24 hour working casualty.
Data were collected from in patient &out patient files of general medicine
department in that hospital and by interviewing the patients.
STUDY DESIGN
A prospective study with questionnaire used to evaluate type 2 diabetes with
co-morbiditiesand awareness levels.
STUDY PERIOD
The study was carried out from May 2013 to February 2014 (10 months)
STUDY POPULATION
The study population consists of 699 diabetic patients those who qualified
the inclusion criteria.
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STUDY CRITERIA
INCLUSION CRITERIA
• Patients with type 2 diabetes mellitus was included in the study
• Both male and female included in the study 
• Patients with existing co-morbidities
EXCLUSION CRITERIA
• Pediatric patient were excluded 
• Emergency care patient excluded 
• Pregnant women are excluded 
• Mentally retarded patient excluded
• Type 1 diabetes mellitus was excluded
• Patient  who have not been able  to  attend at  least  3  visits  to  the hospital
during the study period. 
DATA COLLECTION
Permission was obtained from hospital administration and doctors to conduct
the  study  in  that  Hospital  .The  study  was  carried  using  medical  chart  of  699
randomly  selected  patients  who  had  been  treated  in  the  hospital  and  data  was
collected  from  prescription,  current  medication  chart  and  laboratory  records.
Informed consent was obtained from the patients before the interview.
STUDY PROCEDURES
Research type was descriptive observational study. The data were collected
from 699 cares of patientin first visit, second visit and third visit. In the first visit
patient  will  sign  informed  patent  consent  form  and  asking  questionnaire.The
variables analyzed were general characteristics of the patient genders, Age, current,
medical  history  and  medicine  prescribed  during  hospital  hospitalization.  The
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medication  uses  of  patients  during  hospitalization  were  recorded.  Also  giving
education  and counseling to  the  patients  regarding  dietary changes,exercise,  and
importance of medication adherence etc. in first and second visit. The data collection
of impact of pharmacist education program questionnaire is continuing in the final
visit during this study.
Level-1  
Based on the prescription of the diagnosis co-morbidities were identified.
Level -2 
Interviewto  understand  the  awareness  level  of  the  patient  on  the  co-
morbidities.
Level -3 
Patient awareness program on co-morbidities was initiated 
Level- 4
Follow up on same parameter to understand the impact of patient awareness
program on the patient,the  awareness  level  before  and after  pharmacist’s  patient
education programwas compared and the impact of pharmacist patient’s education
program diabetes was co morbidities.
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STATISTICAL TOOL
The information collected regarding all the selected cases were recorded in a
Master Chart. Data analysis was done with the help of computer using SPSSver:17
2010
Using  this  software  range,  frequencies,  percentages,  means,  standard
deviations, chi square and‘p’ values were calculated. Kruskul Wallis chi-square test
was used to test the significance of difference between quantitative variables and
Yate’s chi square test for qualitative variables. A 'p' value less than 0.05 is taken to
denote significant relationship.
Qualitative responses were obtained for the 6 questions from the Study cases.
In  order  to  make  a  quantitative  analysis,  scores  were  given  to  the  qualitative
responses as follows.
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RESULTS AND DISCUSSION
The study attended to estimate the quality of life in patient suffering from
DM with co morbidities using question air. The improvements of the quality of life
in DM patient with co morbidities are also analyzed in this study and the roll of
pharmacist in patient education program is also determined during the study. The
impact of study and patient education program on those patients were also studied in
detailed.
Diabetes  mellitus  is  one  of  the  most  common  non  communicable
diseasesglobally.  DM can be further  divide in  to  two types,  Type I  and  Type II
diabetes  mellitus.The  Type  II  DM  is  a  chronic  metabolic  disorder  which  is
characterized by insulin resistance,  impaired functions of islets  of  beta cells  and
multiple other metabolic or endocrine abnormalities.  It  is  estimated that  the total
number of people with DM is projected to raise from 171 million in 2000 to 366
million in 2030 and the prevalence is higher in men than in women. The disease can
be dangerous and deadly if  untreated at  proper  period and  may also  have other
complication.
             DM can be more dangerous and deadly when accompanied by other chronic
disease  called  co-morbidities,  these  may  include  cardiovascular  diseases,
retinopathy, neuropathy, nephropathy,DFUand hypertension etc. which may increase
the mortality rate and may also decrease the quality of life.
The  high  rate  of  increasing DM and  co-morbidities  signifies  that  patient
education programs and decreasing this rate is the need for the hour, keeping the
concept in mind a study program was conducted to determine the number of people
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suffering from DM and co-morbidities  and also steps  were taken to  educate the
people about the seriousness of the disease.
The  area  which  I  preferred  for  my  thesis  regarding  DM  and  its  co-
morbidities was Codacal which is located in Malappuram district in Kerala state.
The area is highly populated fast developing area so most of the people are unaware
about the dangerous disease diabetes mellitus and its co-morbidities. CSI Hospital
Codacal  was  the  institution  where  I  performed  the  thesis.  The  patient  who was
diagnosed in the hospital was mainly used for the studies and the PEP. The changes
in their life style and the extent of the disease before and after the education program
were also studied carefully.
Most of the people living in and around Codacal are economically forward
and well settled; most of them are carless about their health so conducting such an
educational research program was very useful in making people aware about DM
and its co-morbidity.
Consumption of alcohol and smoking has been reported as the main cause of
cardiovascular diseases, Neuropathy, Retinopathy, hypertension etc. and these co-
morbidities affect DM in an adverse manner, so smoking and alcohol consumption
of DM patients can be dangerous and should be seen in a more serious manner.
The objective of the study was to determine the prevalence of co-morbidities
in  type  2  diabetes  patients.  The  awareness  level  of  the  patients  about  the  co-
morbidities  of  diabetes  was  also  studied  and  observed.  The  patient  education
program  on  co-morbidities  in  type  2  diabetes  mellitus  was  also  conducted  and
efforts  were  made  to  understand  the  impact  of  pharmacist’s  patient  education
Dept. Of Pharmacy Practice 38 JKKMMRF College of Pharmacy
Chapter 6 Results and Discussion
program on the awareness level of the patients. Clinical outcome of the study was
also determined.
DEMOGRAPHICAL DATA
A total of about 1126 patients were randomly selected for this study, out of
which about 862npeople were suffering from type 2 DM out of the 862 people 699
attended the further studies and patient education program. The rest were avoided
due to lack of regular follow up, Final statistical analysis of the data was done for a
total of 699 patients those who completed the study with regular follow up.
The table 1 shows the demographical  data of the study conducted. It  was
noted that out of the 699 patients who were part of the study 374 were males and
325 were females. The chartclearly describes about the total number of people who
attended the program from different age groups and the chart also gives a clear cut
idea about the number of male and female patients who attended the program from
different age groups and also says about the percentage of males and females from
different age groups who suffers from diabetes mellitus.
Table 1: Age and sex distribution 
Age N=699 % To Total Female Female % Male Male%
21-30 6 0.9 3 0.4 3 0.4
31-40 41 5.9 24 3.4 17 2.4
41-50 112 16.0 53 7.6 59 8.4
51-60 169 24.2 79 11.3 90 12.9
61-70 186 26.6 90 12.9 96 13.7
71-80 118 16.9 44 6.3 74 10.6
80-90 62 8.9 27 3.9 35 5.0
91-100 5 0.7 5 0.7 0 0
325 374
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According to the graphical picture, male patients were more affected to type
2 diabetes mellitus than female patents. The chart says that about 53.5% of patients
who attended the studies were males and about 46.5% were females.
Age distribution
Picture 1: Age distribution
Six people from the age group of 21-30 attended the program out of which
three were males and three were females so it proves that 0.4%males and females
who  suffered from type 2 diabetes mellitus is from this age group. In the age group
of 31-40 forty one people participated in the program, 24 of them where females and
17  were  males  thus  3.4% of  females  from age  group  of  31-40  are  affected  by
diabetes mellitus and 2.4% of male from this age group suffers from the disease.
From the age group of 41-50, hundred and twelve people attended the studies, out of
which 53 were females and 59 were males this means that 7.6% of females and
8.4% of males suffers from type 2 diabetes mellitus are from this age group .169
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people who attended the program were from age group of 51-60 out of which 79
were females and 90 were males so 11.3% females and 12.9% of males are affected
by the disease from this age group.
From the age group of 61-70 hundred and eighty six people were affected, 90
of them were female and 96 of them males, 12.9% of females and 13.7% of males
are affected by type 2 diabetes mellitus from the age group of 61 -70. Forty four
females and 74 males from the age group of 71-80 was present for this study, that is
a total of 118 people from this age group attended this studies,6.3% females and
10.6% males affected to diabetes mellitus are from this age group. From the age
group 80- 90, 62 people attended the program out of which 27 were females and 35
were males, 3.9% of females and 5.0% of males were affected diabetes mellitus are
from this  age  group.  Five  females  from  the  age  group  of  91-100  attended  the
program, 0.5% females affected to the disease is from this age group.
The table clearly describes that most number of people affected to type 2
diabetes mellitus is from the age group of 61-70 and the second largest age group
with the disease is 51-60 and the table also says that males are more prone to DM
than females.
BODY MASS INDEX (BMI)
In table 2 an attempt is made to categories all the patients who took part in
the studies on the basis of body mass index (BMI) for this, BMI range was divided
in to five categories- below normal ,normal, over wait , obesity class I and obesity
class II. Male and female data were separately classified below these categories.
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Table 2: BMI Distribution
Category N=699 % to
Total
Female
% to
Total
(F)
Male
% to
Total
(M)
below normal 37 5.3 18 2.6 19 2.7
Normal 295 42.2 131 18.7 164 23.5
Over wt 230 32.9 114 20.6 116 16.6
Obesity class I 120 17.2 50 7.2 70 10.0
Obesity class II 17 2.4 10 1.4 7 1.0
325 374
A total of 37 people came under the category of below normal in which 18
were females and 19 males thus 2.6% of females and 2.7% of males who took part
in the studies comes under this categories. Under the category of normal range 295
patients were added among them 131 where females and 164 were males that  is
18.7%  females  and  23.5%  males   comes  under  the  categories.  The  over  wait
category has 230 patients in which 114 are females and 116 are males, thus 20.6% of
females and 16.6% of males are under this categories. 
Picture 2: Body Mass Index distribution
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The obesity class one (class I) and obesity class two (class II) had 120 and 17
patients respectively, in which 50 females and 70 males were present in obesity class
I and 10 females and 7 males were present in obesity class II. 7.2% of female and
the 10% of males comes under obesity class one and 1.4% of females and 1% males
come under obesity class II
From the picture it was clear that most of the patients who took part in our
studies were in the normal range and the overweight range of body mass index 
DIABETES CO-MORBIDITIES
Table 3: Diabetes Co-morbidities
Sl
no
Co-morbidity
Total
coun
t
% To
Total
Female Male
No of
patients
% To
Total
No of
patients
% To
Total
1 Hypertension 594 85.0 267 38.2 327 46.8
2 Nephropathy 291 41.6 175 25.0 116 16.6
3 Neuropathy 284 40.6 120 17.2 164 23.5
4 Hyperlipidemia 615 88.0 263 37.6 342 48.9
5 Retinopathy 118 16.9 52 7.4 66 9.4
6 Vertigo 163 23.3 87 12.4 76 10.9
7 Allergic rhinitis 128 18.3 57 8.2 71 10.2
8 Calcium deficiency 286 40.9 128 18.3 158 22.6
9 Vit K deficiency 91 13.0 43 6.2 48 6.9
10 Respiratory disease 158 22.6 76 10.9 82 11.7
11 Gastritis 64 9.2 33 4.7 31 4.4
12 Antifungal drugs 8 1.1 2 0.3 6 0.9
13 Anemia 112 16.0 44 6.3 68 9.7
14 Gout 122 17.5 60 8.6 62 8.9
15
Mood stabilizer 
medicines 173 24.7 88 12.6 85 12.2
16 Parkinson’s disease 87 12.4 37 5.3 50 7.2
17 Pneumonia 16 2.3 6 0.9 10 1.4
18 Thyroid 118 16.9 71 10.2 47 6.7
Table  3  says  about  different  co-morbidities  which were  affected to  those
patients, who were considered for our studies. The table also gives an idea about the
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total number of males and females who were affected to different co-morbidities.
The percentage of patients under each co-morbidity is also given, with separate male
and female percentages.
It is clear that hypertension is a common co-morbidity found in most of the
diabetes  mellitus  patients  Out  of  the  699  patients  who  were  considered  for  the
studies 594 were suffering from hypertension, that is about 85% of patients were
suffering from hypertension 38.2% of females and 46.8% of males who took part in
the studies were suffering from hypertension.
Hyperlipidemia was affected to 615 patients in which 263 were females and
342 were males. This indicates that 88% patients are affected to the disease and
37.6%  females  and  48.9%  males  had  this  co-morbidity.  The  next  reported  co-
morbidity was retinopathy, 118(16.9%) patients suffered from the disease in which
52 were females and 66 were males.
Nephropathy is  co-morbidity,  291 patients were affected to the disease in
which 175 were females and 116 were males. So 41.6% DM patient suffers from
the disease nephropathy. 25% of female and 16.6% male diabetes patients had the
co-morbidity nephropathy. 
Calcium  deficiency  and  vitamin  k  deficiency  was  also  reported  in  DM
patients and their range  was 286 and 91 respectively, that constitute a percentage of
40.9 suffering from calcium deficiency and 13% from vitamin k deficiency.  128
females  (18.3%) and  158 males  (22.6)  suffered from calcium deficiency and 43
females (6.3%) and 48 males (6.9%) suffered from vitamin k deficiency.
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284  patients  had  neuropathy  that  is  a  percentage  of  40.6  patients  had
neuropathy, out of which 120 (17.2%) were females and 164(23.5%) were males. A
problem of mood stabilization was also found in 173 patients, that indicate 24,7%
people  had  this  co-morbidity,  which  included  88  females(12.6%)  and  85  males
(12.2%).It was clear from the table that 163 patients (23.3%) suffered from vertigo
which included 87 females and 76 males, thus 12.4% of females and 10.9% males
were affected with this co-morbidity.
Respiratory problems were noted in 158 patients in whom 76 were females
and 82 were males, which are out of the 26.6% of total affected patients 10.9% were
females and 11.7% weremales. The table clearly indicates that 128 (18.3%) patients
suffered from allergic  problems,  in  which  57 were females  (8.2%) and 71 were
males (10.2%).
Thyroid diseases were found in 118 patients, 71 of them were females and 47
were  males.  The table  also  says  that  16.9 % patients  had  thyroid  problems and
10.2% of then were females and 6.7% were males. Gout was found in 122 patients,
that is a total of 17.5%.the table also says that 60of them were females (8.6%) and
62 were males (8.9%).
Anemia, it can be a deadly and dangerous disease when accompanied with
DM, other  problems like vertigo and cardiovascular  problems also may be seen
along with anemia.  According to the table the disease was found in 112 patients
(16.0%), 44 of them were females and 68 were males, that is 6.3% were females and
9.7% of males were affected by the disease.
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Parkinson’s disease was found in 37 females and 50 males,  a total  of 87
patients suffered from the disease, when describing it according to percentage wise
12.4% of patients were affected to the disease in which 5.3% patients were females
and 7.2 % were males.
The table shows that 64 (9.2%) patients suffered from gastritis out of which
33  were  females(4.7)  and  31  were  males(4.4%)  other  non  DM  problems  like
medicine and some food may also be a reason for the disease.
A total of 16 patients suffered from pneumonia which includes 6 females and
10 males, which are out of the total 2.3% of patients affected 0.9% were females and
1.4% were  males.About  6males  and  2  females  that  is  a  total  of  8  patients  had
antifungal problems. That is only 1.1% had the problem, 0.3% of them were females
and 0.9% were males.
The table clearly describes that hypertension and hyperlipidemia are the most
common  co-morbidities  found  in  diabetes  mellitus  patients,  more  than  99%  of
patients are affected to hypertension and 95% are affected to hyperlipidemia
Table 4 describes about the co-morbidities present in the DM patients. The
table clearly arranges the co-morbidities in descending orderof the people affected.
The  table  gives  information  about  the  total  number  of  people  affected  by  each
co-morbidity and also gives the percentage of affected patients and then arranges all
these data in descending order.
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Table 4: Prevalence of Co-morbidity
Sl no Co-morbidity Total
count
% To
Total
1 Hyperlipidemia 615 88.0
2 Hypertension 594 85.0
3 Nephropathy 291 41.6
4 Calcium deficiency 286 40.9
5 Neuropathy 284 40.6
6 Mood stabilizer medicines 173 24.7
7 Vertigo 163 23.3
8 Respiratory 158 22.6
9 Allergic rhinitis 128 18.3
10 Gout 122 17.5
11 Retinopathy 118 16.9
12 Thyroid 118 16.9
13 Anemia 112 16.0
14 Vit K deficiency 91 13.0
15 Parkinson’s disease 87 12.4
16 Gastritis 64 9.2
17 Pneumonia 16 2.3
18 Antifungal drugs 8 1.1
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Picture 3: Prevalance of  Co-morbidity
According to the table it  is clearly visible that hyperlipidemia is the most
common co-morbidity affected to DM patients.  It  is found that 615 patient were
affected to this particular problem, that is about 88.0% of DM patients who attended
the studies had hyperlipidemia
Hypertension is the next in the list. It is clear that about 594 patients, which
are 85.0% of DM patients, were having the co-morbidity hypertension too. The table
says  about  291  patient  were  affected  by  nephropathy,  about  41.6%  calcium
deficiency is  the  next  most  commonly occurring  co-morbidity.  About  286  were
affected by this problem. That is about 40.9%.
The table next says about neuropathy, 284 were affected by the disease that
is a total of 40.6%.then about 173 was victim of mood stabilizer. That is 24.7%. The
next common co-morbidity, according to the table was vertigo, 163 were reported to
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be vertigo patents (23.3%). Respiratory diseases were the next and 158 patient that
is 22.6% were affected to this problem.
Patient  with  allergic  problem  was  128  that  make  a  percentage  of  18.3.
Thenext  in  the  list  is  gout.  122  were  victims  of  the  disease,  which  is  17.5%.
Retinopathy is the next in the list 118 patient suffered from the retinopathy. That is
16.9%.the  table  also  says  that  thyroid  deficiency  also  had  the  same  number  of
affected patient that of retinopathy. That is 118 and 16.9%. About 112 people had
anemic problem that is a total percentage of 16 % had anemia among the DM patient
who were taken for  the studies.  Vitamin k deficiency comes next  in  the list  91
patient were affected. That is about 13% had vitamin k deficiency.
The table says that 87 suffered from Parkinson’s disease, which is 12.4%.
Next in the list is gastritis. The table indicate that 64 were affected by this problem
(9.2%).  Pneumonia  comes  second  last  in  the  list;  only 10  were  affected  to  the
disease  during  the  study,  which  is  2.3%.antifungal  problem  were  the  other  co-
morbidity, only 1.1% had these co-morbidity table says that only 8 patient had this
problem.
CO-MORBIDITY IN FEMALES
Table 5 gives a detail  idea about the co-morbidities with DM, affected in
females. The table gives an idea about the number of female patients affected by
different co-morbidities. The total percentages of affected females are also given.
The data is then arranged in a descending order.
 The table gives the information that most number of females was affected
with  hypertension.  About  88.2%  were  affected  with  hypertension.  That  is  267
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patients had the disease.  The next in the list  is hyperlipidemia.263 patients were
reported to have this co-morbidity (37.6%)
             Nephropathy comes next in these list 175 patients, which are 25% had this
problem. Deficiency of  calcium was also seen.  About 18.3% that  is  around 128
patients  had  calcium deficiency.  Neuropathy is  the  next;  it  was  reported  in  120
patients with a total percentage of 17.2 suffering from this co morbidity.
Table5: Prevalence of co-morbidity in female patients
Sl no Co-morbidity
Female
No of patients  % To Total
1 Hypertension 267 38.2
2 Hyper lipidemia 263 37.6
3 Nephropathy 175 25.0
4 Calcium deficiency 128 18.3
5 Neuropathy 120 17.2
6 Mood stabilizer medicines 88 12.6
7 Vertigo 87 12.4
8 Respiratory disorder 76 10.9
9 Thyroid 71 10.2
10 Gout 60 8.6
11 Allergic rhinitis 57 8.2
12 Retinopathy 52 7.4
13 Anemia 44 6.3
14 Vit K deficiency 43 6.2
15 Parkinson’s disease 37 5.3
16 Gastritis 33 4.7
17 Pneumonia 6 0.9
18 Antifungal drugs 2 0.3
Mood stabilizer problem was seen in 88 female patients (12.6%). The table
also  shows  that  87  patients  that  are  about  12.4%  had  the  problem  of  vertigo.
Respiratory problem are the next most commonly occurring co morbidity among
female patients.10.9% that is about 76 were suffering from this problem. Thyroid
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problem  were  seen  in  71  patients  that  I  a  percentage  of  10.2  suffers  from
thyroidproblem.
According to the table gout comes next. 60 patients were found to be victim
of the disease (8.6%). The table clearly shows that allergic problems were seen in 57
patients and retinopathy in 52. That becomes a total of 8.2 % allergic and 7.4% of
retinopathy patients.
The next most commonly occurring co-morbidities is anemia was observed
in 44 female patients, 6.3% was anemic patients. Vitamin K deficiency occurs next
in  the  table  43 suffered  from this  problem .that  is  about  6.2  % of  total  female
patients were deficit to vitamin K.
Parkinson’s  disease  and  gastritis  was  observed  in  37  and  33  patients
respectively. That is about 5.3 and 4.7 % female patient were suffering from these
disease  respectively  .pneumonia  takes  the  second  last  position  of  the  most
commonly occurring co-morbidity, only 6 were affected  to this problem (0.9%)
Antifungal disease is the least occurring co-morbidity among female only 2
wasfound to be affected, that is only a percentage of 0.3.
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Picture 4: Prevalence of co-morbidity in female patients
CO-MORBIDITY IN MALES
Table 6 detailed says  about  the  co-morbidity range in  male patients.  The
table  has  the  co-morbidities  which  were  found  in  male  patients,  arranged  in
descending  order  of  number  of  patients  affected.  In  the  table  it  is  listed  that
hyperlipidemia is the most commonly or largely occurring. Co-morbidities among
male patients 342 patients were reported by the disease that is about 48.9%. The
next position is given to hypertension. According to the table 327 male were victim
of hypertension. That is about 46.8%
Table 6:Prevalence of co-morbidity in male patients
Sl no Co-morbidity
Male
No of patients in %
1 Hyperlipidemia 342 48.9
2 Hypertension 327 46.8
3 Neuropathy 164 23.5
4 Calcium deficiency 158 22.6
5 Nephropathy 116 16.6
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6 Mood stabilizer medicines 85 12.2
7 Respiratory 82 11.7
8 Vertigo 76 10.9
9 Allergic rhinitis 71 10.2
10 Anemia 68 9.7
11 Retinopathy 66 9.4
12 Gout 62 8.9
13 Parkinson’s disease 50 7.2
14 Vit K deficiency 48 6.9
15 Thyroid 47 6.7
16 Gastritis 31 4.4
17 Pneumonia 10 1.4
18 Antifungal 6 0.9
The  table  says  that  169  patients  (23.5)  had  neuropathy and  158  patients
(22.6%) were affected by calcium deficiency. nephropathy takes the next position
with about 116 patients getting affected. That is about 176.6 % of males patients had
nephropathy.
Mood stabilizer medicines were seen in 85 male patients (12.2%. Respiratory
problem was  the  next  most  commonly occurring disease;  about  32  patients  had
respiratory problems (11.7%).The table describes that vertigo was affected to 76 and
allergic problem was seen in 71 males respectively. That may be about 10.9% of
vertigo patients and 10.2% of allergic patients. Anemia is the next co-morbidity it
was seen that  68 patients  (9.7%) were  anemic  in  the overall  male patient  seen.
Retinopathy was observed in 66 male patients which makes about 9.4%o of male
retinopathy  patients.  Gout  and  Parkinson’s  disease  was  observed  in  62  and  50
patients respectively. Thus 8.9% of male patients had gout and 7.2%had Parkinson’s
disease.
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Vitamin  K  deficiency  comes  in  the  list  48  were  found  affected  (6.9%).
Thyroid problem was found in 47 male patients (6.7%). The table determines that
gastritis  occurred in 31 males.  That is a  percentage of 4.4.  Pneumonia takes  the
second  least  position  in  the  table  with  10  affected  patients  (1.4%).  Antifungal
problems takes the last position in the table with only 6 people affected and makes a
percentage of 0.9 affected male.
Picture 5: Prevalence of co-morbidity in male patients
PATIENT AWARENESS PROGRAM
Keepingthesefactors  in  mind.  It  is  very  necessary  to  organize  a  patient
education program. Through which a detailed study about the DM patients and co-
morbidities were conducted.
The need for organizing such a program was to make the people aware about
these diseases and its deadly effects which may be caused if not treated properly at
proper time. In the program leaflets were created on the basis of the co-morbidities
and distributed among the patients. Making them aware about the disease, for that
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counseling program was also organized among the patient to used their knowledge
about these co-morbidities and proper instructions were given to them.
From these studies and counseling it was clear that most of the patients were
unaware about the co-morbidities, which can be affecting along with DM. Most of
the peoples are not much bothered about these diseases which can be very dangerous
in some cases if untreated.
The people are mostly busy with their works and day to day activities while
most  of  them  are  often  forgetting  to  do  maintaining  a  healthy  life  style.  The
changing of people towards western culture and fast foods etc. has become a good
reason for  such a  large rate  of  DM patients  and other  dangerous  co-morbidities
which can accompany them.
Patient education program conducted and the each and every data and values
regarding co-morbidity, and the patients were recorded carefully before and after the
program. 
The recorded values  before and after  the patient  education program were
compared carefully to determine whether there was any recordable changes in the
data.
The result was that there was a significant decrease in the co morbidity range
of the patients. After the program the percentage of people in each co morbidity
change was decreased in a notable manner and it was also found that many patients
who attended the program before to take proper steps to stay away from these co-
morbidities and live a healthy life. Most of the people began to control their food
and also began to do exercises.
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Patients with hypertension, anemic and such co-morbidities began to control
their  food and also began to have regularcheck up. People understood about  the
dangerous of these co-morbidities and that significant changes were seen.   
From the dates it  was clear that many patents for eg.  Mainly neuropathic
patients began to be concerned about the problem of the diseases and take steps to
prevent foot ulcer.
          From the dates and record eel changes if was clear that most of the people
were able to understand the importance of co-morbidities and their prevention steps.
From the data if can also be clear that our program had a good impact on the patients
and the program was a success.
THE IMPACT OF PHARMACIST’S PATIENT EDUCATION PROGRAM
The table clearly describes about the diabetes co-morbidities, about its mean 
intervention. The table also says about the standard deviation and the P value of the 
data  regarding the co-morbidities. The table also says about the significance of the 
co-morbidities.
Table 7. : The impact of pharmacist’s patient education program
Co-morbidities Intervention Mean SD P value Significant
Retinopathy
before 3.63 1.26
0.0001 S
after 4.71 1.87
Nephropathy
before 3.64 1.44
0.0001 S
after 4.64 1.40
Neuropathy before 2.91 1.08 0.0001 S
after 4.28 1.03
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Hypertension
before 2.26 1.07
0.0001 S
after 3.30 1.01
Hyperlipidemia
before 1.89 1.03
0.0001 S
after 2.94 0.94
The mean difference of different intervention (before and after the patient
education program) can also be calculated from the table and the percentage can also
be determined if necessary. The table distinctly describes about the 5 co-morbidities
which  includes  retinopathy,  nephropathy,  neuropathy,  hypertension  and  hyper
lipidemia. The mean and SD are described on the basis of the two intervention, that
is before and after the patient education program.
             According to the table the mean value of retinopathy affecter patients before
the patient education program was 3.632 and after was 4.71, the men difference was
found to be 1.078. The calculated standard deviation was about 1.26 and 1.87 before
and after the program respectively. The p value was calculated as 0.0001 and was
found to be significant. In case of nephropathy the mean value was noted to be 3.64
before  the  program and  4.64  after,  thus  the  mean difference  is  1.  The  SD was
recorded as 1.440 and 1.07 respectively before and after the program, the P value is
0.0001 and thus was found to be significant. The mean value is 2.907 and 4.283 for
before and after intervention for neuropathy, the mean difference of the co-morbidity
is  1.376  and  the  SD  before  the  program  was  1.82  and  after  was  1.035  for
neuropathy. The P value was found to be 0.0001 so it is significant.
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 Hypertension,  very  common  and  deadly  co-morbidity  among  diabetes
affected people. 2.259 was the mean value before and 3.303 was the value after
patient education program, the mean difference was 1.044 and SD was 1.07 and
1.010 before and after respectively. It is significant and the P value was 0.0001.
In the case of hyper lipedemia the mean value is 1.894 and 2.937 with a
difference of 1.042 the SD of the co-morbidity recorded is 1.038 before the patient
education  program  and  0.946  after  the  program.  The  P value  is  0.0001  and  is
significant. From the table it is clear that the P value of all the 5 co-morbidities was
0.0001. Since the P value is  below 0.5 it  can be said that all the co-morbidities
described in the table are significant.
Picture 7: The impact of pharmacist’s patient education program
HEMOGLOBIN A1C TEST
Table 8: HbA1c test before and after patient education program.
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Lab test Grand Total  % To Total
HbA1C before 5856.4 837.83
HbA1C after 5255.3 751.83
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The Hba1c level data also has a significant impact by the clinical outcome of
the studies and patient education program. It was found that the Hba1c level before
program was 5856.4, that is about 53%, and the level after the program was 5255.3,
the percentage level was reduced to 47%.thus the clinical outcome of the studies and
patient education program has reduced the % level of Hba1c by 6%.
 From these data, all these co-morbidities were significant and Hba1c level
has  also  reduced  to  a  notable  level  due  to  patient  education  program,  thus  the
program could make a remarkable effect on diabetes affected patient who were used
for these studies.
53%
47%
HEMOGLOBIN A1C TEST
HbA1C before
HbA1C after
Picture 8: HbA1c test before and after patient education program
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CONCLUSION
The main objective of the study was to study the prevalence of co-morbidities in type 2
DM. The awareness level of people and the impact of pharmacist patient education program were
also studied in detail.  Implementation of the patient education program on the co-morbidities
among the type 2 DM patients was also an aim of the study conducted.
Detailed  surveys  about  the  diabetes  affected  patients  and    the  co-morbidities  were
studied  and  recorded,  the  no  of  people  affected  to  different  co-morbidities  were  separately
studied and their percentage were calculated,also their percentage after the studies and the patient
education program were compared and noted.
    The impact of the patient education program on the awareness level of patient was found out.
The significance level  of the co-morbidities were found out, from these data it was seen that all
the co-morbidities were having the P value of about 0.0001, which is below 0.05 thus it was
determined that the intervention by the Pharmacist was significant &  outcome was positive.
Dept. Of Pharmacy Practice 60 JKKMMRF College of Pharmacy
Chapter 6 Results and Discussion
BIBLIOGRAHY
• Altindas M, Cinar C. Promoting primary healing after ray amputation in the diabetic foot:
the plantar dermo-fat pad flap.PlastReconstr Surg. 2005;116(4):1029-1034.
• American Diabetes Association Standards of Medical Care for Persons With 
• American  Diabetes  Association.  Position  Statement:  Diabetic  Nephropathy.  Diabetes
Care 1997;20:S24-S27. 
• Andrew  sto,  mickymarblow,American  diabetes  association,  diabetes  care,2002:25(4)
quality of importance of diabetes program, gesinger health plan, Danville.
• Bodeker  GC,  Ryan  TJ,  Ong  CK.  Traditional  approaches  to  wound
healing. ClinDermatol. 1999;17(1):93-98.
• Burton TM. United HealthCare finds drugs, test are often underutilized. The Wall Street
Journal (Interactive Edition) July 8, 1998. 
• Centers for Disease Control and Prevention (CDC). Prevalence and most common causes
of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;
58: 421-6 
• Centers for Disease Control and Prevention (CDC). Prevalence and most common causes
of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;
58: 421-6 
Dept. Of Pharmacy Practice 61 JKKMMRF College of Pharmacy
Chapter 6 Results and Discussion
• Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with Type 2
diabetes  by  pharmacists  in  primary  care  clinics.  Annals  of  Pharmacotherapy
1998;32:636-641. 
• Cooper  RA,  Hales  E,  Molan  PC.  The  efficacy  of  honey  in  inhibiting  strains  of
Pseudomonas Aeruginosa from infected burns. J Burn Care Rehabil. 2002;23(6):366-370.
• Cooper RA, Molan PC, Harding KG. The sensitivity to honey of Gram-positive cocci of
clinical significance isolated from wounds. J ApplMicrobiol. 2002;93(5):857-863.
• Cynthiya  M. Boyd , JONathandarver  clinical practice guidlines and quality of care for
older patients with multiple comorbid disease, the American medical association 2005
august 10,2005-vol 294 no.6 page no :1094- 1099
• David lau MD phd Canadian journal of diabetes 2011; vol. 35(1): page no 46-53
• Dewsbury  C,  Acharya  S  et  al,  International  journal  of  pharmacy  practice  (2012)
supplement 1: page no: 38-55
• Diabetes Mellitus. Diabetes Care 2000;23(Supplement 1);S32-S42. 
• Fincham JE,  Lofholm PW. Saving Money and Lives  –  Pharmacist  Care for  Diabetes
Patients. America’s Pharmacist 1998;(March):49-52. 
• Bradley EH Fried TR, , Williams CS, Tinetti ME. Functional disability and health care
expenditures for older persons. Arch Intern Med 2001; 161: 2602-7 
• Williams CS Fried TR, Bradley EH, , Tinetti ME. Functional disability and health care
expenditures for older persons. Arch Intern Med 2001; 161: 2602-7 
Dept. Of Pharmacy Practice 62 JKKMMRF College of Pharmacy
Chapter 6 Results and Discussion
• Piaggesi  A Frykberg  RG,  ,  Donaghue  VM  et  al.  Differences  in  treatment  of  foot
ulceration in Boston, USA and Pisa, Italy. Diabetes Res ClinPract 1997;35(1):21-26.
• Danieldubay Hae mi, sonyamitrovich, , The American journal of managed care ; April
2005: vol:11 no.4 page no 253-260
• yin-bun Hwee –lin, , Health and quality of life outcome 2005: 3;2 dio; 10.1186/1477-
7525-5-2
• Isfahan university of medical science ,Isfahan Iran, journal of research in medical science
January 2011; vol .16 (1) ;page no 43-49
• Journal article pharmacology : 2005 ;vol ;25 (12) page no : 1804-1816
• Kalani M, et al. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers.
Long term follow up. J Diabetes Complications. 2002;16(2):153-158.
• Kruse  I,Edelman  S.  Evaluation  and  treatment  of  diabetic  foot  ulcers. Clinical
Diabetes. 2006;24(2):91-93.
• Molan  P.  The  antibacterial  activity  of  honey:1.  The  nature  of  the  antibacterial
activity. Bee World. 1992; 73(1): 5-28.
• O Brien JA, Shomphe LA, Kavanagh PL, et al. Direct medical costs of complications
resulting from Type 2 Diabetes in the U.S. Diabetes Care 1998;21:1122-1128. 
• Ossorio RC Peters AL, Legorreta AP, , Davidson MB. Quality of outpatient care provided
to diabetic patients. Diabetes Care 1996;19:601-606.  
Dept. Of Pharmacy Practice 63 JKKMMRF College of Pharmacy
Chapter 6 Results and Discussion
• Mohan  v  RamachandranA,Jai  MV,  ,  Snehalatha  C  Vishwanathan  M  (1988)  high
prevalence of diabetes in an urban population of South India.BJM  297:587-590
• ,  Snehalatha,  Manoharan  M,  Vijay  V  RamachandranA,Latha  E  (1999)  impact  of
urbanisation  on  the  life  style  and  the  pevalence  of  diabetes  in  native  Asian  Indian
population. Diabetes Res Clin. Practice 44: 207-213
• Rebecca shaw, Jilli, The Australian  Journal of life advanced nursing volume 25:4-august
2008.
• ,  Lipsky  BA,  Gibbons  GW  Reiber  GE.  The  burden  of  diabetic  foot  ulcers. Am  J
Surg. 1998;176(2A suppl):5S-10S.
• Rubin  RJ,  Altman  WM,  Mendelson  DN.  Health  care  expenditures  for  people  with
diabetes  mellitus,  1992.  Journal  of  Clinical  Endocrinology  and  Metabolism
1994;78:809A-809F. 
• Ryan  J,  Kennth  E  The  prevalence  of  comorbid  depression  in  adults  with  diabetes,
American diabetes association, diabetes care march  2001 vol.24 page no 561-587.
• Sarah wild, MB bachir et al diabetes care: vol.27 no.5: May 2005: page no. 1047-1053
• Jitendrasinha Shampaghosh , Indian journal of medical research 132, august 2010 page
no 195-200
• Stella UA,Martin Bleu,American diabetes association, diabetes care ; January 2009; vol ;
32; page no; 87-94
Dept. Of Pharmacy Practice 64 JKKMMRF College of Pharmacy
Chapter 6 Results and Discussion
• Stephen  gloury,  EdvardLeu  Baylor  university  medical  center;  dallas,  tx,  USA post
graduate medicine (impact 1.97) may 2010; volume 122(3); 71-80.
• Stephy R Juli, Raisasamual  Diabetes care ; volume 28, number 4, April  2005 page no:
771 – 776.
• Summary of the Second Report of the National Cholesterol Education Program (NCEP)
Expert  Panel  on  Detection,  Evaluation  and  Treatment  of  High  Blood  Cholesterol  in
Adults. JAMA 1993;269:3015-3023. 
• Shibley MCH, Cary CC,  et  al  The Asheville  Project.  Pharmacy Times 1998(October
supplement).   Berringer  R,.  Outcomes  of  a  Community  Pharmacy-  Based  Diabetes
Monitoring Program. Journal of the American Pharmaceutical Association. 1999;39:791-
7. 
• Weiman  TJ,   Su  Y  Smiell  JM.  Efficacy  and  safety  of  topical  gel  formulation  of
recombinant  human platelet–derived  growth  factor-BB (becaplermin)  in  patients  with
chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-
blind study. Diabetes Care. 1998;21(5):822-827.
• Weiner JP, Garnick DW Parente ST, Garnick DW, et al. Variation in office-based quality.
JAMA 1995;273:1503-1508. 
• Wijesinghe M, Weatherall M, Perrin K, Beasley R. Honey in the treatment of burns: a
systemic review and meta-analysis of its efficacy. N Z Med J. 2009; 122(1295):47-60.
• Wolinsky FD, , Fitzgerald JF, Callahan CM Johnson RJ. Changes in functional status and
the risks of subsequent nursing home placement and death. J Gerontol 1993;48:S94-101 
Dept. Of Pharmacy Practice 65 JKKMMRF College of Pharmacy
Chapter 6 Results and Discussion
• Wolinsky FD, Fitzgerald JF, Johnson RJ. Changes in functional status and the risks of
subsequent nursing home placement and death. J Gerontol 1993;48:S94-101.
• Yoon nyumkim, department of internal medicines and medical informatics june 2012 vol:
27 No. 2 page no 197-202.
Dept. Of Pharmacy Practice 66 JKKMMRF College of Pharmacy
Chapter 6 Results and Discussion
PREVALENCE OF CO-MORBIDITIES IN TYPE 2 DIABETES MELLITUS PATIENTS, THE AWARENESS LEVEL
AND THE IMPACT OF PHARMACIST’S PATIENT EDUCATION PROGRAM
NAME: _____________________ AGE: _____
SEX: _______   EDUCATION: ____________
MOBILE NUMBER: __________________ HEIGHT (in cm): _______
WEIGHT (in kg): ___________ BMI: ___________
BMI CLASS: _____________    
DIABETES DIAGNOSED 1ST ON: _____________
MEDICATION PRESCRIBED 
LAST THREE READING LAB 
REPORTS
HbA1C Date
Value
Pre-prandial Date
Value
Post-prandial Date
Value
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Name of the medicine Dose schedule
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PATIENT CONSENT / ASSENT FORM
I have read/been briefed on the study “Prevalence of co-morbidities in type
2  diabetes  mellitus  patients,  the  awareness  level  and  the  impact  of
pharmacist’s  patient  education  program  At  Malappuram District,  Kerala”
and  I  voluntarily  agree  to  participate  in  this  study which  may  or  may not  be
beneficial   me.  Its  general  purpose,  potential  benefits,  possible  hazards,  and
inconveniences have been explained to me up to my satisfaction. I have the option
to withdraw from the study at any stage. I here by give my consent for this study.
Rm³ CXp-hm-bn¨p a\-Ên-em¡n “Prevalence of co-morbidities in type
2  diabetes  mellitus  patients,  the  awareness  level  and  the  impact  of
pharmacist’s patient education program At Malappuram District, Kerala” F¶
Cu ]T\¯nsâ Cu `mK-am-sW¶v kzta-[b  a\-Ên-em-¡p-¶p.  ]n¶oSv {]tXy-
In¨v ImcWw ImWn-¡msX Xs¶ F\n¡v CXnÂ \n¶pw ]n³·m-dm³ Ah-Im-i-
ap-v. Cu ]T-\-¯nsâ `mK-am-hm³ Rm³ k½-Xn-¡p-¶p F¶v km£y-s¸-Sp-¯p-
Ibpw sN¿p-¶p.  
Name of Patient: Signature of patient
Place:
Date:
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HYPER TENSION 
1. Are you aware that uncontrolled diabetes can complicate hypertension?
ZoÀL-Im-e- {]-talw càk-½À±w IqSm³ Imc-W-am-¡p-
¶Xv \n§Ä¡vAdnbmtam ?
Yes N  
No
2. Are you feeling dizziness or vertigo?
\n§Ä¡vXe-I-d¡w A\p-`-h-s¸-Sm-dp-tm ?
Yes N 
N
o
3. Do you sweat suddenly with out any reason?
\n§ÄHcpImc-WhpwCÃmsX s]s«¶vhnbÀ¡m-dptm ?
Yes N 
N
o
4. Do you feel confused all time? 
\n§Ä¡vAe-kX A\p-`-h-s¸-Sm-dptm ?
Yes N 
N
o
5. Has your breath become shorter?
\n§Ä¡v {]tXyIImcWwanÃmsXXs¶ izmkwFSp-¡p-¶-XnÂ 
_p²n-ap-v A\p`-h-s¸-Sm-dptm ?
Yes N 
N
o
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NEUROPATHY
1. Are you aware that uncontrolled diabetes can affect Neuropathy?
ZoÀL-Ime {]talw \mSn -kw-_ÔambAkp-J-¯n\v Imc-W-
am-Ip-sa¶v \n§Ä¡-dn-bmtam ?
Yes N 
N
o
2. Can you feel the sensation of that on your foot?
\n§-fpsSImenÂsXmSp¶ kv]Ài\w Adnbm³ km[n-¡m-dptm?
Yes N 
N
o
3. Have you felt any swelling or edema on you legs?
ImenÂ \ntcmAsÃ-¦nÂXSnt¸mhcm-dptm ?
Yes N 
N
o
4. If there is a cut/injury? in your feet does it heat as usual?
IenÂapdnhvh¶mÂ km[m-cW DW-§-¶Xv 
t]mseAXvDW§mdptm ?
Yes N 
N
o
5. Are you aware of precautions to be taken for prevention of diabetes foot ulcer?
{]talwaqewDm-Ip¶  Imenseapdnhvhcm-Xn-cn-
¡m-\pÅamÀK-§Ä \n§Â¡-dn-bmtam ? 
Yes N 
N
o
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RETINOPATHY
1. Are you aware that uncontrolled diabetes can affect your vision?
ZoÀL-Ime {]talwImgvNsb _m[n¡p-¶p F¶Xv \n§Ä¡-dn-btam
?
Yes N 
N
o
2. Have you felt that your vision is decreasing suddenly?
\n§Ä¡vImgvN s]s«¶vIpd-bp-¶-Xmbn A\p-`-h-s¸-«n-Sptm ?
Yes N 
N
o
3. Have you felt that your vision is becoming smoky or cloudy?
\n§-fpsSImgvN ]pIaqSn-bXv t]msetbmAsÃ-¦nÂ s]mSn-]-
S-e-¯n-\n-S-bn-eq-sStbmt\m¡p-¶Xv t]mse A\p-`-h-s¸-«n-
Sptm ?
Yes N 
N
o
4. Are you feeling paining in eye ball?
\n§fpsSI®nsâ a[y-`m-K¯vthZ\ hcm-dptm ?
Yes N 
N
o
5. Can you read properly?
\n§Ä¡vIrXy-ambnhmbn-¡m³ Ign-bp-¶ptm ?
Yes N 
N
o
6. Do you have headache normal vision?
\n§Ä¡v k[m-cWhmbn-¡p-t¼mÄ Xe-th-Z\ hcm-cptm ?
Yes N
N
o
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NEPHROPATHY
1. Are you aware that uncontrolled diabetes can affect your kidney?
\nb-{´-W-an-Ãm¯ {]talwhr¡-tc-K-¯n\v Imc-W-am-Ip-
¶Xv \n§Ä¡vAndnbmtam ?
Yes N 
N
o
2. Are you feeling tired and weak?
\n§Ä¡vAkz-`m-hnI £oWw A\p-`-h-s¸-Sm-dptm ?
Yes N 
N
o
3. Is your appetite poor?
\n§Ä¡vhni¸vIpdhv A\p-`-h-s¸-«n-«ptm ?
Yes N 
N
o
4. Is there is edema or swelling on your legs?
\n§-fpsSImenÂ \ntcmAsÃ¦nÂXSnt¸m A\p-`-h-s¸-«n-Sptm
?
Yes N 
N
o
5. Are you having any kind of discomfort for urination?#S
\n§Ä¡vaq{X-sam-gn-¡p-t¼mÂ GsX-¦nepwcoXn-bn-epÅ 
_p²n-ap«v A\p`h-s¸-«n-«ptm ?
Yes N 
N
o
6. Do you feel any trouble while sleeping?
Xm¦Ä \ÃXv t]mseDd-§-dptm ?
Yes N 
N
o
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HYPERLIPIDEMIA
1. Are you aware that uncontrolled diabetes can complicate hyper lipidemia?
\nb-{´-W-an-Ãm¯ {]talwsIgp¸vk_Ô-ambAkp-J-¯n\v Imc-
W-am-¡p-¶Xv Adn-bmtam ?
Yes N 
N
o
2. Has your weight increased suddenly?
ASp-¯-Im-e-¯mbn s]s«¶v \n§fpsSicoc `mcwIqSn-bn-«pt-
m ?
Yes N 
N
o
3. Is your knee and angle joint paining?
\n§-fpsSImÂap«n\pw tPmbânepwthZ-\-h-cm-cptm ?
Yes N 
N
o
4.Is your chest paining?
ITn-\-ta-dnbtPmen sN¿p-t¼mÄ AsÃ-¦nÂhymgmaw 
sN¿p-t¼mÂ s\©v thZ\ Dm-Im-dptm ?.
Yes N 
N
o
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